Erlotinib 150/100 mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Drug Information

Target Indication

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Clinical Trial

Last updated: 9/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Related Pipeline

Migraine Without Aura

Anxiety Disorders

Infections

ST Elevation Myocardial Infarction

Generalized Anxiety Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts